In the past week, FGEN stock has gone down by -17.69%, with a monthly decline of -58.53% and a quarterly surge of 19.89%. The volatility ratio for the week is 12.23%, and the volatility levels for the last 30 days are 15.63% for FibroGen Inc The simple moving average for the past 20 days is -36.63% for FGEN’s stock, with a -16.86% simple moving average for the past 200 days.
Is It Worth Investing in FibroGen Inc (NASDAQ: FGEN) Right Now?
Moreover, the 36-month beta value for FGEN is 0.89. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 5 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for FGEN is 91.83M and currently, short sellers hold a 5.65% of that float. On April 24, 2024, FGEN’s average trading volume was 2.81M shares.
FGEN) stock’s latest price update
The stock price of FibroGen Inc (NASDAQ: FGEN) has dropped by -6.14 compared to previous close of 1.14. Despite this, the company has seen a fall of -17.69% in its stock price over the last five trading days. InvestorPlace reported 2024-03-20 that Stocks are at the mercy of many factors, and often, prices are just a poor earnings report or a negative headline away from a significant drop. There are times when nobody has any way of preparing.
Analysts’ Opinion of FGEN
Many brokerage firms have already submitted their reports for FGEN stocks, with BofA Securities repeating the rating for FGEN by listing it as a “Underperform.” The predicted price for FGEN in the upcoming period, according to BofA Securities is $2 based on the research report published on August 08, 2023 of the previous year 2023.
FGEN Trading at -44.12% from the 50-Day Moving Average
After a stumble in the market that brought FGEN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -94.72% of loss for the given period.
Volatility was left at 15.63%, however, over the last 30 days, the volatility rate increased by 12.23%, as shares sank -59.47% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -60.81% lower at present.
During the last 5 trading sessions, FGEN fell by -17.69%, which changed the moving average for the period of 200-days by -60.37% in comparison to the 20-day moving average, which settled at $1.6100. In addition, FibroGen Inc saw 20.73% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at FGEN starting from Wettig Thane, who purchase 50,000 shares at the price of $1.91 back on Mar 07 ’24. After this action, Wettig Thane now owns 470,178 shares of FibroGen Inc, valued at $95,470 using the latest closing price.
Henderson Jeffrey William, the Director of FibroGen Inc, sale 2,000 shares at $1.03 during a trade that took place back on Sep 01 ’23, which means that Henderson Jeffrey William is holding 28,866 shares at $2,060 based on the most recent closing price.
Stock Fundamentals for FGEN
Current profitability levels for the company are sitting at:
- -1.91 for the present operating margin
- 0.87 for the gross margin
The net margin for FibroGen Inc stands at -1.93. The total capital return value is set at -1.37. Equity return is now at value -42790.17, with -55.00 for asset returns.
Based on FibroGen Inc (FGEN), the company’s capital structure generated -1.03 points at debt to capital in total, while cash flow to debt ratio is standing at -3.03. The debt to equity ratio resting at -0.51. The interest coverage ratio of the stock is -18.15.
Currently, EBITDA for the company is -259.28 million with net debt to EBITDA at -0.22. When we switch over and look at the enterprise to sales, we see a ratio of 1.1. The receivables turnover for the company is 3.6for trailing twelve months and the total asset turnover is 0.35. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.52.
Conclusion
To wrap up, the performance of FibroGen Inc (FGEN) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
